David Henry Aggen

13PUBLICATIONS
163CO-AUTHORS
NanomedicineCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersNanomaterials
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Nov 03, 2026
Location, Location, Location: Membranous Nectin-4 as a Biomarker for Enfortumab Vedotin.

|Feb 02, 2026
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.

Brendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran

|Dec 13, 2025
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Rana R McKay, Sumanta Pal, Wanling Xie

|Nov 03, 2025
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.

David H Aggen, Meredith McKean, Jean H Hoffman-Censits

|Sep 11, 2025
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.

Andrea Necchi, Matthew D Galsky, Nazli Dizman

|Sep 13, 2024
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.

Matthew C Dallos, Aleksandar Z Obradovic, Patrick McCann

Pageof 3

Frequent Collaborators

7 joint publications

Jonathan Rosenberg

6 joint publications

Hikmat Al-Ahmadie

4 joint publications

Samuel Funt

4 joint publications

Bernard H Bochner